NASDAQ:AKBA
Akebia Therapeutics Stock News
$1.24
-0.0200 (-1.59%)
At Close: May 01, 2024
CAMBRIDGE, Mass., March 30, 2021 /PRNewswire/ -- Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease,
CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the Pharma
Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month
08:00am, Thursday, 11'th Mar 2021
CAMBRIDGE, Mass., March 11, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, cele
Bumble, NextEra Energy, Wheaton Precious Metals and More Monday Afternoon Analyst Calls
12:20pm, Monday, 08'th Mar 2021
With the trading day about halfway over, the broad markets were pushing higher on the day.
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2020 Results - Earnings Call Transcript
11:56pm, Thursday, 25'th Feb 2021
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2020 Results - Earnings Call Transcript
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
01:41pm, Thursday, 18'th Feb 2021
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon's Analyst Calls
03:34pm, Friday, 29'th Jan 2021
With the trading day practically over, the broad markets were sliding into the weekend.
Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options
09:47am, Wednesday, 16'th Dec 2020
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth
08:00am, Wednesday, 09'th Dec 2020
CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™
09:37am, Wednesday, 18'th Nov 2020
CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today a
CAMBRIDGE, Mass., Nov. 16, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today a
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript
12:35pm, Friday, 06'th Nov 2020
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 03'rd Nov 2020
CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted
Packaging Machinery Market Procurement Intelligence Report With COVID-19 Impact Analysis | Global Forecasts, 2020-2024 | SpendEdge
12:00am, Tuesday, 20'th Oct 2020
Packaging Machinery market will register an incremental spend of about USD 17 billion, growing at a CAGR of 6.37% during the five-year forecast period
Packaging Machinery Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
12:00am, Friday, 18'th Sep 2020
The Packaging Machinery market will register an incremental spend of about $17 billion, growing at a CAGR of 6.37%
